Efficacy of topical Interferon Alfa- 2b used as an adjunct in the management of primary OSSN

---

Original Article

Author Details : Gursimran Kaur*, Prasoon Pandey, Nirpal Shukla, Ram Shukla, Jasjit Kaur

Volume : 7, Issue : 3, Year : 2021

Article Page : 250-256

https://doi.org/10.18231/j.ijooo.2021.052

Suggest article by email

Get Permission

---

Abstract

Objective: To assess the efficacy of topical interferon alfa-2b as an adjunct therapy in the management of primary ocular surface squamous neoplasia (OSSN).
Materials and Methods : Clinically visible OSSN on slit lamp examination in 21 patients (21 tumors) was managed with topical interferon alfa-2b, 1 million IU/mL, 4times daily for a period of one month, before subjecting the patients to definitive surgery. The patients were periodically observed, over a period of 6 months. Tumor control and complications were evaluated according to American Joint Committee on Cancer classification. A significant reduction in size, was noted in smaller tumors. Final diagnosis and staging was done after histopathological examination of the surgically excised tumour, which had been excised with a 4mm margin. Bigger extensive lesion did not show appreciable response in terms of appearance or reduction of size.
Results: Tumor size was found to be reduced significantly in 19 out of 21 tumors (%) following topical interferon alfa-2b treatment for a period of 1 month, from the presentation. Of the 19 tumors, tumor surface area was reduced 44% (median). Two patients (8.3%) did not respond to the treatment.
Based on American Joint Committee on Cancer classification, significant reduction was achieved in 2 of 3 Tis (67%), 17 of 20 T3 (85%), 19 of 23 N0 (83%), and 19 of 23 M0 (83%) category tumors.
Conclusion: According to American Joint Committee on Cancer classification, significant reduction with topical interferon alfa-2b can be achieved in 67% of Tis, 85% of T3, and 83% of all OSSN.
 
Keywords: OSSN, Interferon alfa 2b, AJCC

How to cite : Kaur G, Pandey P, Shukla N, Shukla R, Kaur J, Efficacy of topical Interferon Alfa- 2b used as an adjunct in the management of primary OSSN. IP Int J Ocul Oncol Oculoplasty 2021;7(3):250-256

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.